NovelMed is currently seeking investments or partners to advance its pipeline of anti-complement antibodies. Our lead candidates are now moving to Phase II clinical trial in Q2 of 2022 for various clinical indications. Our primary indication is PNH but given the unique mechanism of action associated with our antibody platform it has the potential to address a number of additional clinical indications. NovelMed is open to discussions for the license of a subset, or the entire complement platform for one or more indications.
- Phase I clinical trial for NM8074 to complete in Q1, 2022
- Phase II trial for NM5072 to begin in 2022
- Advanced stage antibody platform has the potential to address multiple indications
- Strong intellectual property with a number of current and pending patents
- Undiluted ownership structure
We are very interested in licensing our drugs to a partner for their development as novel therapies for rare diseases
NovelMed Therapeutics is a biotechnology company that conducts cutting-edge research and develops therapeutics for complement-mediated diseases. As a company, we are driven by our commitment to patients and a shared vision to provide innovative new therapies for unmet medical needs. We are focused on developing transformative treatment options for patients suffering from orphan and non-orphan diseases.
NovelMed Therapeutics, Inc.
11000 Cedar Avenue
Cleveland, Ohio 4106
Tel: (216)707 1775 Email: email@example.com